Kamada's Human Rabies Immune Globulin Successfully Meets Primary Endpoint in U.S. Pivotal Phase 2/3 Clinical Trial as Post-Exposure Treatment

Kamada Ltd. KMDA reports that the pivotal Phase 2/3 clinical trial with the Company's human rabies immune globulin (IgG or KamRAB™ or KedRAB™) therapy as a post-exposure treatment for rabies successfully met the trial's primary endpoint of non-inferiority when measured against an IgG reference product. The Company expects to file a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) in mid-2016. KamRAB is the brand name for Kamada's human rabies immune globulin currently marketed for this indication in 10 countries worldwide. Kamada has a strategic agreement with Kedrion S.p.A for the clinical development and marketing of its IgG product, See full press release